Patients with atopic dermatitis who had not received biologics prior to treatment with Opzelura were able to avoid biologics ...

The ruxolitinib cream met its primary end point as a treatment for prurigo nodularis in one phase 3 trial but fell short in ...

Two posters presented at the 2025 American Academy of Dermatology Annual Meeting reaffirmed the impact of ruxolitinib cream ...

Incyte’s ruxolitinib franchise, made up of blockbuster JAK inhibitor Jakafi and its topical counterpart Opzelura, have been the company’s driving focus for years. Now, with Jakafi approaching ...

Opzelura (ruxolitinib) is now the first alternative to steroid drugs for vitiligo, a chronic autoimmune disease that causes depigmentation of skin and affects around 1.5 million people in the US.

OPZELURA (ruxolitinib cream) has shown strong market growth, driven by increasing adoption in dermatological conditions like vitiligo and atopic dermatitis. Its unique positioning as the first ...

She was excited to try OPZELURA ® (ruxolitinib) cream 1.5%—a treatment she now prescribes to her appropriate patients. OPZELURA is a non-steroidal, twice-daily cream that is FDA approved for ...

The company's topical cream Opzelura also showed strong growth, with net product revenues jumping 48% YoY to $162 million. "2024 was an important year for Incyte, with a 15% increase in total ...

Incyte stock was one of the biggest decliners on the S&P 500 Monday after the drugmaker's fourth-quarter adjusted profit and projections for 2025 sales of key medications fell short of analysts' ...

Incyte has build a solid foundation over the past decade with hematology drug Jakafi, and the approval of the same active ingredient as oral dermatology drug Opzelura is expanding the firm's focus ...

Jakafi Net Sales: $2.8 billion in 2024, up 8% year-over-year. Opzelura Revenue: $508 million in 2024, a 50% increase from 2023. Q4 2024 Revenue: $1.2 billion, up 16% from Q4 2023. Cash Position ...